Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shuhei Teranishi
Observed names:
S. Teranishi,
SHUHEI TERANISHI
Institution:
Kanagawa Cancer Center
Observed institutions:
Yokohama City University Medical Center,
Yokohama City University Hospital,
Kanagawa Cancer Center,
National Hospital Organization Yokohama Medical Center,
Yokohama City University
ORCID:
0000-0003-2365-144X
Observed ORCID:
0000-0003-2365-144X
OpenAlex ID:
A5023700895
MicroRNA ‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer
2020
·
Seigo Katakura
, Nobuaki Kobayashi
, et al.
·
Thoracic Cancer
·
21
PDF
Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib
2022
·
Shuhei Teranishi
, Chihiro Sugimoto
, et al.
·
Thoracic Cancer
·
20
Identification of Biomarkers for Non–small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor
2020
·
SOUSUKE KUBO
, NOBUAKI KOBAYASHI
, et al.
·
Anticancer Research
·
19
PDF
Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan
2020
·
Seigo Katakura
, Nobuaki Kobayashi
, et al.
·
Tuberculosis
·
17
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
2021
·
Hiromi Matsumoto
, Nobuaki Kobayashi
, et al.
·
Thoracic Cancer
·
15
Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer
2021
·
Ryota Ushio
, Masaki Yamamoto
, et al.
·
Internal Medicine
·
15
PDF
Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma
2022
·
SHUHEI TERANISHI
, CHIHIRO SUGIMOTO
, et al.
·
Cancer Diagnosis & Prognosis
·
14
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib
2024
·
Shigeki Umemura
, Hibiki Udagawa
, et al.
·
Journal of Thoracic Oncology
·
12
Real‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer
2024
·
Ayami Kaneko
, Nobuaki Kobayashi
, et al.
·
Thoracic Cancer
·
11
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
2023
·
Nobuaki Kobayashi
, Kenji Miura
, et al.
·
Cancers
·
11
PDF
T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
2021
·
Chisato Kamimaki
, Nobuaki Kobayashi
, et al.
·
Thoracic Cancer
·
11
PDF
MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer
2025
·
Ayami Kaneko
, Nobuaki Kobayashi
, et al.
·
Translational Lung Cancer Research
·
9
Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
2020
·
Shuhei Teranishi
, Nobuaki Kobayashi
, et al.
·
Thoracic Cancer
·
7
PDF
Comparison of the slow‐pull and aspiration methods of endobronchial ultrasound‐guided transbronchial needle aspiration for next‐generation sequencing‐compatible tissue collection in non‐small cell lung cancer
2023
·
Yukihito Kajita
, Shuhei Teranishi
, et al.
·
Cancer Medicine
·
5
PDF
Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan
2019
·
Shuhei Teranishi
, Nobuaki Kobayashi
, et al.
·
Journal of Infection and Chemotherapy
·
5
Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer
2023
·
Sousuke Kubo
, Nobuaki Kobayashi
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
4
PDF
Afatinib + bevacizumab combination therapy in EGFR ‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label , phase II , multicenter, single‐arm trial
2020
·
Nobuaki Kobayashi
, Hisashi Hashimoto
, et al.
·
Thoracic Cancer
·
4
PDF
Efficacy and safety of intrapleural administration of sodium bicarbonate in patients with acute empyema and complicated parapneumonic effusion: protocol for a prospective, single-arm, interventional study
2025
·
Yuichiro Suzukawa
, Shuhei Teranishi
, et al.
·
BMC Infectious Diseases
·
2
Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
2023
·
Nobuyuki Hirama
, Masaki Yamamoto
, et al.
·
Thoracic Cancer
·
2
PDF
Primary tracheal small‐cell carcinoma detected 11 months after surgery for pulmonary large‐cell neuroendocrine carcinoma: A case report
2023
·
Chihiro Sugimoto
, Shuhei Teranishi
, et al.
·
Thoracic Cancer
·
2
Thymic atypical carcinoid tumors with elevated mitotic counts in a patient with multiple endocrine neoplasia: A case report
2023
·
Shuntaro Hiro
, Shuhei Teranishi
, et al.
·
Thoracic Cancer
·
2
Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study
2025
·
Suguru Muraoka
, Nobuaki Kobayashi
, et al.
·
Translational Lung Cancer Research
·
1
Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)
2025
·
Yuji Uehara
, Hiroki Izumi
, et al.
·
Lung Cancer
·
1
Rapid detection of non-small cell lung cancer driver mutations using droplet digital polymerase chain reaction analysis of bronchial washings: a prospective multicenter study
2025
·
Kohei Somekawa
, Nobuaki Kobayashi
, et al.
·
Translational Lung Cancer Research
·
1
Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study
2024
·
Anna Tanaka
, Shuhei Teranishi
, et al.
·
Frontiers in Oncology
·
1
PDF
Show more works
View as search
Works count:
42
Citation count:
212
H-index:
11
I10-index:
11
Year
Topic
Type